Anti-Human TNFRSF14 (Clone CPTC-TNFRSF14-3) – Purified No Carrier Protein

TNFRSF14 synthetic peptide EDEYPVGSEC[cam]C[cam]PK

This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added.

Liquid

Purified antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

This antibody may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles.

Research Use Only

2 – 8° C Wet Ice

FSAI165R-9F8 activity is directed against human TNFRSF14, peptide sequence EDEYPVGSECCPK.

CPTC-TNFRSF14-3

TNFRSF14 is a type I transmembrane glycoprotein that regulates T cell immune responses, T cell survival, dendritic cell homeostasis, autoimmune-mediated inflammatory disease responses, attenuation of B cell responses, and host defense against pathogens such as herpes simplex virus- 1 (HSV-1)¹. TNFRSF14 does so by activating inflammatory and inhibitory signaling pathways as both a receptor and ligand, thereby creating diverse intrinsic and bidirectional signaling pathways. Interacting molecules include TNF-related ligands, LIGHT, herpes simplex virus glycoprotein D, lymphotoxin- α, and immunoglobulin superfamily proteins BTLA and CD160. Additionally, TNFRSF14 may play roles in sensory neuron development and adipocyte metabolism. Furthermore, TNFRSF14 is one of two major routes for HSV-1 entry into human and mouse cells.

Dysregulation of TNFRSF14 is thought to contribute to autoimmune pathogenesis of rheumatoid arthritis, inflammatory bowel disease (IBD), and asthma as well as lead to a breakdown of TNFRSF14-LIGHT¹ and TNFRSF14-BTLA² regulation of host anti-tumor immune responses. TNFRSF14 blockade has been investigated as an immunotherapy to promote allotransplantation, tumor clearance in LIGHT- and/or BTLA-expressing cancer, airway remodeling in asthma, and reduced pathogenesis in IBD.

FSAI165R-9F8 was generated in mouse using a synthetic peptide derived from human TNFRSF14 that is carbamidomethylated at both cysteines, EDEYPVGSEC[cam]C[cam]PK³. FSAI165R-9F8 was developed for use in immuno-MRM assays. FSAI165R-9F8 is not suitable for reverse phase protein array use or Western blot analysis⁴.

https://antibodies.cancer.gov/detail/CPTC-TNFRSF14-3#CPTC-TNFRSF14-3

TNFRSF14 is widely expressed, with high expression in lung, spleen, and thymus. TNFRSF14 is expressed in most lineages of hematopoietic cells, a subpopulation of B cells and monocytes, naïve T cells, epithelial cells, and sensory neurons.

TRAF2, TRAF3, TRAF5, CD160, LTA, TNFSF14, BTLA, herpes simplex virus 1/HHV-1 and HHV-2envelope glycoprotein D

1 Steinberg MW, Cheung TC, Ware CF. Immunol Rev. 244(1):169-187. 2011.
2 Guruprasad P, Carturan A, Zhang Y, et al. Nat Immunol. 25(6):1020-1032. 2024.
3 Whiteaker JR, Lundeen RA, Zhao L, et al. Front Immunol. 12:765898. 2021.
4 https://antibodies.cancer.gov/detail/CPTC-TNFRSF14-3#CPTC-TNFRSF14-3